Research ArticleArticle
Psychological and Pain Sensitization Characteristics Are Associated With Patellofemoral Osteoarthritis Symptoms: The Multicenter Osteoarthritis Study
Natalie J. Collins, Tuhina Neogi, Bill Vicenzino, Ali Guermazi, Frank W. Roemer, Cora E. Lewis, James C. Torner, Michael C. Nevitt and Joshua J. Stefanik
The Journal of Rheumatology March 2020, jrheum.190981; DOI: https://doi.org/10.3899/jrheum.190981
Natalie J. Collins
The Multicenter Osteoarthritis Study was funded by the National Institutes of Health (NIH; U01-AG18820, U01-AG18832, U01-AG18947, U01-AG19069, and AR-47785). J. Stefanik was supported by NIH/NIGMS U54-GM104941 and K23-AR070913. T. Neogi was supported by K24-AR070892, P60-AR047785, and R01 AR062506. N. Collins was supported by an Arthritis Queensland Fellowship (2018) and The University of Queensland Postdoctoral Fellowship (2015-17). N. Collins, PT, PhD, B. Vicenzino, PT, PhD, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia; T. Neogi, MD, PhD, A. Guermazi, MD, PhD, School of Medicine, Boston University, Boston Massachusetts, USA; F.W. Roemer, MD, Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany; C.E. Lewis, MD, MSPH, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.C. Torner, PhD, Department of Epidemiology, The University of Iowa, Iowa City, Iowa, USA; M.C. Nevitt, MPH, PhD, Department of Epidemiology and Biostatistics, University of California San Francisco, California, USA; J.J. Stefanik, PT, PhD, Department of Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, Massachusetts, USA. A. Guermazi is the President and shareholder of Boston Imaging Core Lab (BICL), LLC, and consultant to Pfizer, Merck Serono, GE, TissueGene, OrthoTrophix, AstraZeneca, and Sanofi. F. Roemer is a Chief Medical Officer and shareholder of BICL, LLC. Address correspondence to Dr. N.J. Collins, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD 4072, Australia. Email: n.collins1@uq.edu.au. Accepted for publication January 14, 2020.
Tuhina Neogi
The Multicenter Osteoarthritis Study was funded by the National Institutes of Health (NIH; U01-AG18820, U01-AG18832, U01-AG18947, U01-AG19069, and AR-47785). J. Stefanik was supported by NIH/NIGMS U54-GM104941 and K23-AR070913. T. Neogi was supported by K24-AR070892, P60-AR047785, and R01 AR062506. N. Collins was supported by an Arthritis Queensland Fellowship (2018) and The University of Queensland Postdoctoral Fellowship (2015-17). N. Collins, PT, PhD, B. Vicenzino, PT, PhD, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia; T. Neogi, MD, PhD, A. Guermazi, MD, PhD, School of Medicine, Boston University, Boston Massachusetts, USA; F.W. Roemer, MD, Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany; C.E. Lewis, MD, MSPH, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.C. Torner, PhD, Department of Epidemiology, The University of Iowa, Iowa City, Iowa, USA; M.C. Nevitt, MPH, PhD, Department of Epidemiology and Biostatistics, University of California San Francisco, California, USA; J.J. Stefanik, PT, PhD, Department of Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, Massachusetts, USA. A. Guermazi is the President and shareholder of Boston Imaging Core Lab (BICL), LLC, and consultant to Pfizer, Merck Serono, GE, TissueGene, OrthoTrophix, AstraZeneca, and Sanofi. F. Roemer is a Chief Medical Officer and shareholder of BICL, LLC. Address correspondence to Dr. N.J. Collins, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD 4072, Australia. Email: n.collins1@uq.edu.au. Accepted for publication January 14, 2020.
Bill Vicenzino
The Multicenter Osteoarthritis Study was funded by the National Institutes of Health (NIH; U01-AG18820, U01-AG18832, U01-AG18947, U01-AG19069, and AR-47785). J. Stefanik was supported by NIH/NIGMS U54-GM104941 and K23-AR070913. T. Neogi was supported by K24-AR070892, P60-AR047785, and R01 AR062506. N. Collins was supported by an Arthritis Queensland Fellowship (2018) and The University of Queensland Postdoctoral Fellowship (2015-17). N. Collins, PT, PhD, B. Vicenzino, PT, PhD, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia; T. Neogi, MD, PhD, A. Guermazi, MD, PhD, School of Medicine, Boston University, Boston Massachusetts, USA; F.W. Roemer, MD, Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany; C.E. Lewis, MD, MSPH, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.C. Torner, PhD, Department of Epidemiology, The University of Iowa, Iowa City, Iowa, USA; M.C. Nevitt, MPH, PhD, Department of Epidemiology and Biostatistics, University of California San Francisco, California, USA; J.J. Stefanik, PT, PhD, Department of Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, Massachusetts, USA. A. Guermazi is the President and shareholder of Boston Imaging Core Lab (BICL), LLC, and consultant to Pfizer, Merck Serono, GE, TissueGene, OrthoTrophix, AstraZeneca, and Sanofi. F. Roemer is a Chief Medical Officer and shareholder of BICL, LLC. Address correspondence to Dr. N.J. Collins, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD 4072, Australia. Email: n.collins1@uq.edu.au. Accepted for publication January 14, 2020.
Ali Guermazi
The Multicenter Osteoarthritis Study was funded by the National Institutes of Health (NIH; U01-AG18820, U01-AG18832, U01-AG18947, U01-AG19069, and AR-47785). J. Stefanik was supported by NIH/NIGMS U54-GM104941 and K23-AR070913. T. Neogi was supported by K24-AR070892, P60-AR047785, and R01 AR062506. N. Collins was supported by an Arthritis Queensland Fellowship (2018) and The University of Queensland Postdoctoral Fellowship (2015-17). N. Collins, PT, PhD, B. Vicenzino, PT, PhD, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia; T. Neogi, MD, PhD, A. Guermazi, MD, PhD, School of Medicine, Boston University, Boston Massachusetts, USA; F.W. Roemer, MD, Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany; C.E. Lewis, MD, MSPH, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.C. Torner, PhD, Department of Epidemiology, The University of Iowa, Iowa City, Iowa, USA; M.C. Nevitt, MPH, PhD, Department of Epidemiology and Biostatistics, University of California San Francisco, California, USA; J.J. Stefanik, PT, PhD, Department of Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, Massachusetts, USA. A. Guermazi is the President and shareholder of Boston Imaging Core Lab (BICL), LLC, and consultant to Pfizer, Merck Serono, GE, TissueGene, OrthoTrophix, AstraZeneca, and Sanofi. F. Roemer is a Chief Medical Officer and shareholder of BICL, LLC. Address correspondence to Dr. N.J. Collins, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD 4072, Australia. Email: n.collins1@uq.edu.au. Accepted for publication January 14, 2020.
Frank W. Roemer
The Multicenter Osteoarthritis Study was funded by the National Institutes of Health (NIH; U01-AG18820, U01-AG18832, U01-AG18947, U01-AG19069, and AR-47785). J. Stefanik was supported by NIH/NIGMS U54-GM104941 and K23-AR070913. T. Neogi was supported by K24-AR070892, P60-AR047785, and R01 AR062506. N. Collins was supported by an Arthritis Queensland Fellowship (2018) and The University of Queensland Postdoctoral Fellowship (2015-17). N. Collins, PT, PhD, B. Vicenzino, PT, PhD, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia; T. Neogi, MD, PhD, A. Guermazi, MD, PhD, School of Medicine, Boston University, Boston Massachusetts, USA; F.W. Roemer, MD, Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany; C.E. Lewis, MD, MSPH, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.C. Torner, PhD, Department of Epidemiology, The University of Iowa, Iowa City, Iowa, USA; M.C. Nevitt, MPH, PhD, Department of Epidemiology and Biostatistics, University of California San Francisco, California, USA; J.J. Stefanik, PT, PhD, Department of Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, Massachusetts, USA. A. Guermazi is the President and shareholder of Boston Imaging Core Lab (BICL), LLC, and consultant to Pfizer, Merck Serono, GE, TissueGene, OrthoTrophix, AstraZeneca, and Sanofi. F. Roemer is a Chief Medical Officer and shareholder of BICL, LLC. Address correspondence to Dr. N.J. Collins, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD 4072, Australia. Email: n.collins1@uq.edu.au. Accepted for publication January 14, 2020.
Cora E. Lewis
The Multicenter Osteoarthritis Study was funded by the National Institutes of Health (NIH; U01-AG18820, U01-AG18832, U01-AG18947, U01-AG19069, and AR-47785). J. Stefanik was supported by NIH/NIGMS U54-GM104941 and K23-AR070913. T. Neogi was supported by K24-AR070892, P60-AR047785, and R01 AR062506. N. Collins was supported by an Arthritis Queensland Fellowship (2018) and The University of Queensland Postdoctoral Fellowship (2015-17). N. Collins, PT, PhD, B. Vicenzino, PT, PhD, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia; T. Neogi, MD, PhD, A. Guermazi, MD, PhD, School of Medicine, Boston University, Boston Massachusetts, USA; F.W. Roemer, MD, Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany; C.E. Lewis, MD, MSPH, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.C. Torner, PhD, Department of Epidemiology, The University of Iowa, Iowa City, Iowa, USA; M.C. Nevitt, MPH, PhD, Department of Epidemiology and Biostatistics, University of California San Francisco, California, USA; J.J. Stefanik, PT, PhD, Department of Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, Massachusetts, USA. A. Guermazi is the President and shareholder of Boston Imaging Core Lab (BICL), LLC, and consultant to Pfizer, Merck Serono, GE, TissueGene, OrthoTrophix, AstraZeneca, and Sanofi. F. Roemer is a Chief Medical Officer and shareholder of BICL, LLC. Address correspondence to Dr. N.J. Collins, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD 4072, Australia. Email: n.collins1@uq.edu.au. Accepted for publication January 14, 2020.
James C. Torner
The Multicenter Osteoarthritis Study was funded by the National Institutes of Health (NIH; U01-AG18820, U01-AG18832, U01-AG18947, U01-AG19069, and AR-47785). J. Stefanik was supported by NIH/NIGMS U54-GM104941 and K23-AR070913. T. Neogi was supported by K24-AR070892, P60-AR047785, and R01 AR062506. N. Collins was supported by an Arthritis Queensland Fellowship (2018) and The University of Queensland Postdoctoral Fellowship (2015-17). N. Collins, PT, PhD, B. Vicenzino, PT, PhD, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia; T. Neogi, MD, PhD, A. Guermazi, MD, PhD, School of Medicine, Boston University, Boston Massachusetts, USA; F.W. Roemer, MD, Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany; C.E. Lewis, MD, MSPH, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.C. Torner, PhD, Department of Epidemiology, The University of Iowa, Iowa City, Iowa, USA; M.C. Nevitt, MPH, PhD, Department of Epidemiology and Biostatistics, University of California San Francisco, California, USA; J.J. Stefanik, PT, PhD, Department of Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, Massachusetts, USA. A. Guermazi is the President and shareholder of Boston Imaging Core Lab (BICL), LLC, and consultant to Pfizer, Merck Serono, GE, TissueGene, OrthoTrophix, AstraZeneca, and Sanofi. F. Roemer is a Chief Medical Officer and shareholder of BICL, LLC. Address correspondence to Dr. N.J. Collins, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD 4072, Australia. Email: n.collins1@uq.edu.au. Accepted for publication January 14, 2020.
Michael C. Nevitt
The Multicenter Osteoarthritis Study was funded by the National Institutes of Health (NIH; U01-AG18820, U01-AG18832, U01-AG18947, U01-AG19069, and AR-47785). J. Stefanik was supported by NIH/NIGMS U54-GM104941 and K23-AR070913. T. Neogi was supported by K24-AR070892, P60-AR047785, and R01 AR062506. N. Collins was supported by an Arthritis Queensland Fellowship (2018) and The University of Queensland Postdoctoral Fellowship (2015-17). N. Collins, PT, PhD, B. Vicenzino, PT, PhD, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia; T. Neogi, MD, PhD, A. Guermazi, MD, PhD, School of Medicine, Boston University, Boston Massachusetts, USA; F.W. Roemer, MD, Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany; C.E. Lewis, MD, MSPH, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.C. Torner, PhD, Department of Epidemiology, The University of Iowa, Iowa City, Iowa, USA; M.C. Nevitt, MPH, PhD, Department of Epidemiology and Biostatistics, University of California San Francisco, California, USA; J.J. Stefanik, PT, PhD, Department of Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, Massachusetts, USA. A. Guermazi is the President and shareholder of Boston Imaging Core Lab (BICL), LLC, and consultant to Pfizer, Merck Serono, GE, TissueGene, OrthoTrophix, AstraZeneca, and Sanofi. F. Roemer is a Chief Medical Officer and shareholder of BICL, LLC. Address correspondence to Dr. N.J. Collins, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD 4072, Australia. Email: n.collins1@uq.edu.au. Accepted for publication January 14, 2020.
Joshua J. Stefanik
The Multicenter Osteoarthritis Study was funded by the National Institutes of Health (NIH; U01-AG18820, U01-AG18832, U01-AG18947, U01-AG19069, and AR-47785). J. Stefanik was supported by NIH/NIGMS U54-GM104941 and K23-AR070913. T. Neogi was supported by K24-AR070892, P60-AR047785, and R01 AR062506. N. Collins was supported by an Arthritis Queensland Fellowship (2018) and The University of Queensland Postdoctoral Fellowship (2015-17). N. Collins, PT, PhD, B. Vicenzino, PT, PhD, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia; T. Neogi, MD, PhD, A. Guermazi, MD, PhD, School of Medicine, Boston University, Boston Massachusetts, USA; F.W. Roemer, MD, Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany; C.E. Lewis, MD, MSPH, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.C. Torner, PhD, Department of Epidemiology, The University of Iowa, Iowa City, Iowa, USA; M.C. Nevitt, MPH, PhD, Department of Epidemiology and Biostatistics, University of California San Francisco, California, USA; J.J. Stefanik, PT, PhD, Department of Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, Massachusetts, USA. A. Guermazi is the President and shareholder of Boston Imaging Core Lab (BICL), LLC, and consultant to Pfizer, Merck Serono, GE, TissueGene, OrthoTrophix, AstraZeneca, and Sanofi. F. Roemer is a Chief Medical Officer and shareholder of BICL, LLC. Address correspondence to Dr. N.J. Collins, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD 4072, Australia. Email: n.collins1@uq.edu.au. Accepted for publication January 14, 2020.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Psychological and Pain Sensitization Characteristics Are Associated With Patellofemoral Osteoarthritis Symptoms: The Multicenter Osteoarthritis Study
Natalie J. Collins, Tuhina Neogi, Bill Vicenzino, Ali Guermazi, Frank W. Roemer, Cora E. Lewis, James C. Torner, Michael C. Nevitt, Joshua J. Stefanik
The Journal of Rheumatology Mar 2020, jrheum.190981; DOI: 10.3899/jrheum.190981
Psychological and Pain Sensitization Characteristics Are Associated With Patellofemoral Osteoarthritis Symptoms: The Multicenter Osteoarthritis Study
Natalie J. Collins, Tuhina Neogi, Bill Vicenzino, Ali Guermazi, Frank W. Roemer, Cora E. Lewis, James C. Torner, Michael C. Nevitt, Joshua J. Stefanik
The Journal of Rheumatology Mar 2020, jrheum.190981; DOI: 10.3899/jrheum.190981